These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31248778)

  • 41. Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice.
    Cristofanilli M; Rosenthal H; Cymring B; Gratch D; Pagano B; Xie B; Sadiq SA
    Exp Neurol; 2014 Nov; 261():620-32. PubMed ID: 25111532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of integrated Yoga and Physical therapy on audiovisual reaction time, anxiety and depression in patients with chronic multiple sclerosis: a pilot study.
    Chobe S; Bhargav H; Raghuram N; Garner C
    J Complement Integr Med; 2016 Sep; 13(3):301-309. PubMed ID: 27337744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
    Brañas P; Jordan R; Fry-Smith A; Burls A; Hyde C
    Health Technol Assess; 2000; 4(27):1-61. PubMed ID: 11074395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Framework of Care in Multiple Sclerosis, Part 2: Symptomatic Care and Beyond.
    Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
    Int J MS Care; 2017; 19(1):42-56. PubMed ID: 28243186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Update on the Role of Matrix Metalloproteinases in the Pathogenesis of Multiple Sclerosis.
    Boziki M; Grigoriadis N
    Med Chem; 2018 Feb; 14(2):155-169. PubMed ID: 28875862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging immunopharmacological targets in multiple sclerosis.
    Farjam M; Zhang GX; Ciric B; Rostami A
    J Neurol Sci; 2015 Nov; 358(1-2):22-30. PubMed ID: 26440421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of complementary and alternative medicine in patients with multiple sclerosis in Germany.
    Gotta M; Mayer CA; Huebner J
    Complement Ther Med; 2018 Feb; 36():113-117. PubMed ID: 29458916
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of complementary medicines and therapies on maternal anxiety and depression in pregnancy: A systematic review and meta-analysis.
    Smith CA; Shewamene Z; Galbally M; Schmied V; Dahlen H
    J Affect Disord; 2019 Feb; 245():428-439. PubMed ID: 30423471
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems.
    Dolati S; Babaloo Z; Jadidi-Niaragh F; Ayromlou H; Sadreddini S; Yousefi M
    Biomed Pharmacother; 2017 Feb; 86():343-353. PubMed ID: 28011382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
    Karussis D
    J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The relationship between physical activity and symptoms of fatigue, mood, and perceived cognitive impairment in adults with multiple sclerosis.
    Mayo CD; Miksche K; Attwell-Pope K; Gawryluk JR
    J Clin Exp Neuropsychol; 2019 Sep; 41(7):715-722. PubMed ID: 31096850
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of a 4-month Ananda Yoga program on physical and mental health outcomes for persons with multiple sclerosis.
    Salgado BC; Jones M; Ilgun S; McCord G; Loper-Powers M; van Houten P
    Int J Yoga Therap; 2013; (23):27-38. PubMed ID: 24165521
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.
    Filippi M; Rocca MA
    J Neurol; 2005 Nov; 252 Suppl 5():v16-24. PubMed ID: 16254697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complementary and alternative medicine in multiple sclerosis.
    Bowling AC
    Continuum (Minneap Minn); 2010 Oct; 16(5 Multiple Sclerosis):78-89. PubMed ID: 22810599
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The place of transcranial direct current stimulation in the management of multiple sclerosis-related symptoms.
    Ayache SS; Chalah MA
    Neurodegener Dis Manag; 2018 Dec; 8(6):411-422. PubMed ID: 30451080
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-MS autoimmune demyelination.
    Cikes N; Bosnic D; Sentic M
    Clin Neurol Neurosurg; 2008 Nov; 110(9):905-12. PubMed ID: 18928881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biotherapies in multiple sclerosis: a step toward remyelination and neuroprotection?
    Dubessy AL; Zujovic V; Papeix C; Stankoff B
    Rev Neurol (Paris); 2014 Dec; 170(12):770-8. PubMed ID: 25459127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.
    Dulamea AO
    Adv Exp Med Biol; 2017; 958():91-127. PubMed ID: 28093710
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms.
    Christogianni A; Bibb R; Davis SL; Jay O; Barnett M; Evangelou N; Filingeri D
    Temperature (Austin); 2018; 5(3):208-223. PubMed ID: 30377640
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.